Tneurodx

T-NeuroDx operates in the Alzheimer’s diagnostics and biomarker segment, with a focus on blood-based detection rather than imaging-led assessment or later-stage symptom monitoring. Its stated differentiation is the use of dysfunctional and pathologic T-cell signals, particularly hiT Cells, as an early biological indicator associated with Alzheimer’s disease progression. The company’s AlzheimerGuard assay is intended to support preclinical detection, patient stratification, and clinical-trial enrollment. This gives T-NeuroDx a potentially distinct angle within a market that also includes blood-based amyloid and tau testing, imaging providers, and broader neurodegenerative disease diagnostics. T-NeuroDx therefore appears to remain an early-stage, validation-focused participant rather than an established clinical diagnostics provider. Its collaboration with the USC Alzheimer’s Therapeutic Research Institute and planned presentation of human data at AAIC 2026 are relevant credibility and evidence-building steps. The company’s strongest market distinction is its immune-cell biology approach and its intended use across early detection and pharmaceutical clinical research, while its principal risks are scientific validation, assay standardization, regulatory clearance, and conversion of research utility into routine clinical use.

T-NeuroDx’s trajectory shows a gradual progression from foundational research toward a defined diagnostic product and clinical validation strategy. Founded in 2018, the company has developed a blood-based approach centered on dysfunctional T cells and later identified AlzheimerGuard as its lead assay. The $500,000 National Institutes of Health grant announced on Aug 13, 2025 provided non-dilutive support for Alzheimer’s biomarker research and remains the company’s only disclosed funding round. Leadership changed materially on Sep 15, 2025, when Michael Reed became CEO and Chairman after serving as Chief Development Officer. That appointment was followed by a Sep 23, 2025 strategic reorganization that separated treatment development into Ortega NeuroRx, narrowing T-NeuroDx’s operating focus. The next major inflection point came on Apr 15, 2026, when AlzheimerGuard was publicly announced alongside a research collaboration with the USC Alzheimer’s Therapeutic Research Institute. By Jun 4, 2026, the company was preparing to present human data at AAIC 2026, suggesting movement from conceptual biomarker work toward external clinical evidence. The company remains small, with an employee range of one to ten and three highlighted current positions. Future growth depends on validation results, additional grant or investment support, regulatory progress, and adoption by clinical-trial sponsors.